Recent Finacing
Recent Raise
Herantis Pharma develops HER-096, a CDNF‑like biologic for Parkinson’s, conducting a phase 1b Finland trial (24 patients) comparing twice‑weekly injections to placebo, collecting blood and CSF biomarkers.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Herantis Pharma.
